News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study
youtube.com
Jul 26, 2024, 19:39

Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study

Andrea Necchi, Associate Professor at Vita-Salute San Raffaele University, shared on X:

“IDO1 inhibition was ineffective in urothelial carcinoma.

Pembrolizumab and epacadostat/placebo for cis-ineligible urothelial carcinoma:

ECHO-307/KEYNOTE-672 study, BMC Cancer, also negatively tested in neoadjuvant setting.”

Source: Andrea Necchi/X

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

Authors: Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar and Ronald de Wit.

Andrea Necchi

Andrea Necchi Arjun V. Balar Avivit Peer BMC Cancer Boris Y. Alekseev Calvin Jia cancer Dmytro Trukhin ECHO-307/KEYNOTE-672 study epacadostat Francis X. Parnis Howard Gurney Jason Clark Maria De Santis Michiel S. Van der Heijden Mihaela Munteanu OncoDaily Oncology pembrolizumab Petros Grivas Raya Leibowitz Ritesh Kataria Ronald de Wit urothelial carcinoma Vita-Salute San Raffaele University
Special Coverage
Science
Dec 21, 2024, 07:05
Naseema Gangat: Practical prognostic tool for the current standard of care in older/unfit AML
Blog
Dec 21, 2024, 05:54
LCC in Spanish: LALCA 2024 Highlights
Blog
Dec 21, 2024, 05:50
The Opportunities Are Endless: CU Cancer Center leader Enrique Soto Pérez de Celis signs key international agreement
Insight
Dec 21, 2024, 05:42
Raffaella Casolino: How to integrate cancer into crisis?
Insight
Dec 21, 2024, 05:01
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Blog
Dec 21, 2024, 05:01
Omolola Salako: A year ago, Pearl Oncology Specialist Hospital became a 24-hour, 10-bed cancer center
Science
Dec 21, 2024, 04:57
Alexandre Chan: Updates on repurposing riluzole as a treatment for cancer-related cognitive impairment
Blog
Dec 21, 2024, 04:55
Milan Mishkovikj: The Patient at the Center - Value-Based Healthcare in Oncology
Insight
Dec 21, 2024, 04:52
Do national cancer control plans address care and research for children and AYAs - SIOP
Insight
Dec 21, 2024, 04:36
A holistic global strategy for incorporating cancer care into crisis response initiatives - The Institute of Cancer and Crisis
Opinion
Dec 21, 2024, 03:42
The Dorcas Cancer Foundation's 12 Days of Thankful Giving
Blog
Dec 21, 2024, 03:31
The future of cancer diagnostics with Robotic Bronchoscopy - CLIRNET